These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 20504164)

  • 21. Preclinical data released on PI.
    AIDS Patient Care STDS; 2003 Sep; 17(9):483-4. PubMed ID: 14596252
    [No Abstract]   [Full Text] [Related]  

  • 22. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?
    Bagchi S; Kempf MC; Westfall AO; Maherya A; Willig J; Saag MS
    Clin Infect Dis; 2007 Jan; 44(1):135-8. PubMed ID: 17143829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
    J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Monitoring anti-retroviral treatment].
    Miró JM; Pumarola T; Soriano V; Bouza E
    Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():44-50. PubMed ID: 9053027
    [No Abstract]   [Full Text] [Related]  

  • 25. HIV-1 load quantitation: a 17-year perspective.
    Holodniy M
    J Infect Dis; 2006 Sep; 194 Suppl 1():S38-44. PubMed ID: 16921471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Running with scissors: using antiretroviral therapy without monitoring viral load.
    Smith DM; Schooley RT
    Clin Infect Dis; 2008 May; 46(10):1598-600. PubMed ID: 18419496
    [No Abstract]   [Full Text] [Related]  

  • 27. Benchmarks for antiretroviral therapy.
    Cohen OJ; Fauci AS
    J Clin Invest; 2000 Mar; 105(6):709-10. PubMed ID: 10727438
    [No Abstract]   [Full Text] [Related]  

  • 28. [Resistance investigations during HIV-therapy is necessary].
    Schattenfroh S
    Dtsch Med Wochenschr; 1998 Feb; 123(7):A7. PubMed ID: 9505940
    [No Abstract]   [Full Text] [Related]  

  • 29. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
    Marcello A; Giacca M
    Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
    [No Abstract]   [Full Text] [Related]  

  • 30. Detection and significance of minority quasispecies of drug-resistant HIV-1.
    Metzner KJ
    J HIV Ther; 2006 Dec; 11(4):74-81. PubMed ID: 17578210
    [No Abstract]   [Full Text] [Related]  

  • 31. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection.
    Flandre P; Chappey C; Marcelin AG; Ryan K; Maa JF; Bates M; Seekins D; Bernard MC; Calvez V; Molina JM
    J Infect Dis; 2007 Feb; 195(3):392-8. PubMed ID: 17205478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantifying the activity of anti-HIV treatment in silico.
    Ribeiro RM
    Nat Med; 2012 Mar; 18(3):355-6. PubMed ID: 22395700
    [No Abstract]   [Full Text] [Related]  

  • 33. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.
    Sampah ME; Shen L; Jilek BL; Siliciano RF
    Proc Natl Acad Sci U S A; 2011 May; 108(18):7613-8. PubMed ID: 21502494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Surrogate endpoints in clinical studies exemplified by HIV infection].
    Furrer H
    Schweiz Med Wochenschr; 1998 Jul; 128(27-28):1079-88. PubMed ID: 9691341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the inhibitory quotient in HIV therapy.
    Hoefnagel JG; Koopmans PP; Burger DM; Schuurman R; Galama JM
    Antivir Ther; 2005; 10(8):879-92. PubMed ID: 16430193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Instantaneous inhibitory potential and inhibitory quotient show a modest association with virologic outcome: is either a useful surrogate for clinical drug efficacy?
    MacArthur RD
    Clin Infect Dis; 2010 Jul; 51(1):99-100. PubMed ID: 20504164
    [No Abstract]   [Full Text] [Related]  

  • 38. Predictors of virologic response to ritonavir-boosted protease inhibitors.
    Marcelin AG; Flandre P; Peytavin G; Calvez V
    AIDS Rev; 2005; 7(4):225-32. PubMed ID: 16425962
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.